Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

787 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

NCT01040130

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.37.6171 Boehringer Ingelheim Investigational Site Daw Park, South Australia, Australia
  • 1222.37.6174 Boehringer Ingelheim Investigational Site Clayton, Victoria, Australia
  • 1222.37.6173 Boehringer Ingelheim Investigational Site Heidelberg, Victoria, Australia
  • 1222.37.6172 Boehringer Ingelheim Investigational Site Melbourne, Victoria, Australia
View all 19 locations
View Trial Details
Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

NCT01040793

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.38.4380 Boehringer Ingelheim Investigational Site Hallein, Austria
  • 1222.38.4381 Boehringer Ingelheim Investigational Site Leoben, Austria
  • 1222.38.32004 Boehringer Ingelheim Investigational Site Brussels, Belgium
  • 1222.38.32002 Boehringer Ingelheim Investigational Site Edegem, Belgium
View all 19 locations
View Trial Details
Completed

Actuation Indicator Trial in Patients With COPD

NCT00928746

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 244.2507.0107 Boehringer Ingelheim Investigational Site Lafayette, Louisiana, United States
  • 244.2507.0106 Boehringer Ingelheim Investigational Site Easley, South Carolina, United States
  • 244.2507.0102 Boehringer Ingelheim Investigational Site Gaffney, South Carolina, United States
  • 244.2507.0104 Boehringer Ingelheim Investigational Site Greenville, South Carolina, United States
View Trial Details
Completed

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

NCT00846768

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.26.32008 Boehringer Ingelheim Investigational Site Genk, Belgium
  • 1222.26.32006 Boehringer Ingelheim Investigational Site Ghent, Belgium
  • 1222.26.32007 Boehringer Ingelheim Investigational Site Hasselt, Belgium
  • 1222.26.31002 Boehringer Ingelheim Investigational Site Eindhoven, Netherlands
View Trial Details
Completed

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00931385

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.24.24011 Boehringer Ingelheim Investigational Site Tampa, Florida, United States
  • 1222.24.24009 Boehringer Ingelheim Investigational Site Overland Park, Kansas, United States
  • 1222.24.24007 Boehringer Ingelheim Investigational Site Lafayette, Louisiana, United States
  • 1222.24.24002 Boehringer Ingelheim Investigational Site Cincinnati, Ohio, United States
View Trial Details
Completed

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040728

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.40.11003 Boehringer Ingelheim Investigational Site Jasper, Alabama, United States
  • 1222.40.11001 Boehringer Ingelheim Investigational Site Clearwater, Florida, United States
  • 1222.40.11002 Boehringer Ingelheim Investigational Site Tampa, Florida, United States
  • 1222.40.49401 Boehringer Ingelheim Investigational Site Berlin, Germany
View Trial Details
Completed

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

NCT01040689

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.39.32003 Boehringer Ingelheim Investigational Site Genk, Belgium
  • 1222.39.32001 Boehringer Ingelheim Investigational Site Ghent, Belgium
  • 1222.39.32002 Boehringer Ingelheim Investigational Site Hasselt, Belgium
  • 1222.39.45001 Boehringer Ingelheim Investigational Site Hvidovre, Denmark
View all 15 locations
View Trial Details

Related conditions